The following is a summary of chemotherapy-related guidelines and may be found in the ICD-9-CM Official Guidelines for Coding and Reporting, effective October 1, 2009, pages 23-26: Assign code V58.11, Encounter for antineoplastic chemotherapy, as the principal diagnosis if a patient is admitted solely for chemotherapy administration.
T45.1X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Adverse effect of antineoplastic and immunosup drugs, init. The 2019 edition of ICD-10-CM T45.1X5A became effective on October 1, 2018.
If a patient is admitted only to receive chemotherapy, sequence code V58.11 as the principal diagnosis. Sequence the malignancy (primary or secondary) as the principal diagnosis if a patient is admitted for staging the malignancy or a procedure such as thoracentesis even though chemotherapy may be administered.
Unspecified adverse effect of unspecified drug, medicinal and biological substance Short description: Adv eff med/biol sub NOS. ICD-9-CM 995.20 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 995.20 should only be used for claims with a date of service on or before September 30, 2015.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
1 for Encounter for antineoplastic chemotherapy and immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Report ICD-10 code Z01. 818, Encounter for other preprocedural examination (is defined as Encounter for preprocedural examination NOS and Encounter for examinations prior to antineoplastic chemotherapy), when the test is performed as a baseline study before chemotherapy. List Z01. 818 as your primary diagnosis code.
ICD-9-CM Diagnosis Code 199.1 : Other malignant neoplasm without specification of site.
If a patient admission/encounter is solely for the administration of chemotherapy, immunotherapy or external beam radiation therapy assign code Z51. 0, Encounter for antineoplastic radiation therapy, or Z51. 11, Encounter for antineoplastic chemotherapy, or Z51.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
Z5111 - ICD 10 Diagnosis Code - Encounter for antineoplastic chemotherapy - Market Size, Prevalence, Incidence, Quality Outcomes, Top Hospitals & Physicians.
11, Encounter for antineoplastic chemotherapy; or Z51.
ICD-9-CM Diagnosis Code 202.8 : Other malignant lymphomas.
ICD-9 code 162.9 for Malignant neoplasm of bronchus and lung unspecified is a medical classification as listed by WHO under the range -MALIGNANT NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGANS (160-165).
A malignant neoplasm (NEE-oh-plaz-um) is another term for a cancerous tumor. The term “neoplasm” refers to an abnormal growth of tissue. The term “malignant” means the tumor is cancerous and is likely to spread (metastasize) beyond its point of origin.
198.7 Metastasis to adrenal gland 198.5 Metastasis to bone and/or marrow 198.3 Metastasis to brain and/or spinal cord 197.7 Metastasis to liver 197.0 Metastasis to lung 196.9 Metastasis to lymph nodes NOS 198.4 Metastasis to meninges (carcinomatous meningitis) 197.3 Metastasis to pleura (malignant effusion) 197.6 Metastasis to retro/peritoneum
Note that billing codes with a * are not billable without the extra digit, which usually specifies anatomic distribution in the case of lymphoma.
V42.81 Bone marrow replaced by transplant (post-transplant) 996.85 Complications bone marrow transplant (e.g graft vs. host) V59.3 Donor, bone marrow V59.02 Donor, blood stem cells V42.82 Peripheral stem cells replaced by transplant (post-transplant)
Sequence anemia as the principal diagnosis when the admission is for anemia management associated with the malignancy or the therapy and the treatment is directed at only the anemia. The anemia code assignment will depend on the specific type of anemia documented.
If a patient is admitted only to receive chemotherapy, sequence code V58.11 as the principal diagnosis. Sequence the malignancy (primary or secondary) as the principal diagnosis if a patient is admitted for staging the malignancy or a procedure such as thoracentesis even though chemotherapy may be administered.
Sequence dehydration as the principal diagnosis when the admission is for managing dehydration due to the malignancy or the therapy and only the dehydration is being treated. Sequence the malignancy as the principal diagnosis when a patient is admitted for surgical removal of a malignancy followed by chemotherapy.
Assign 285.22, Anemia in neoplastic disease, for anemia due to malignancy. Antineoplastic-chemotherapy-induced anemia is classified to 285.3. Do not use 285.22 for anemia due to chemotherapy. Also, it is unnecessary to assign E933.1, Antineoplastic and immunosuppressive drug, along with 285.3 since the adverse effect of chemotherapy information is ...
Chemotherapy uses powerful drugs in an attempt to eliminate cancer cells in the body. However, it also kills other fast-growing cells such as hair and blood cells, causing side effects such as hair loss and anemia.
The company and its representatives do not assume any responsibility for reimbursement decisions or claims denials made by providers or payers as the result of the misuse of this coding information. More information about 3M Health Information Systems is available at www.3mhis.com or by calling 800-367-2447.